Novo Nordisk A/s

Jens Kaalby Thomsen

Birgit Wieczorek

Birgitte Schjellerup Wulff

Kilian Waldemar Conde Frieboes

Soeren Oestergaard

Carsten Jessen

Morten Schlein

Christian Poulsen

Dorte Bjerre Steensgaard

Anne Plum

Anne Sofie Kajær Markussen

Søren ØStergaard

Anne Sofie Kjær Marcussen

Anne Sofie Kjær Markussen

The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

HPYY(1-36) having a beta-homoarginine substitution at position 35

The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Selective PYY compounds and uses thereof

Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.

Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide

Growing community of inventors

Hellerup, Denmark

Jens Kaalby Thomsen